The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Experimental Therapeutics at Mount Sinai team up with Regeneron on antibody research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE EXPERIMENTAL THERAPEUTICS INSTITUTE at the Icahn School of Medicine at Mount Sinai and Regeneron Pharmaceuticals Inc. entered into an agreement with the goal of accelerating the discovery of fully-human antibodies directed against therapeutic targets being researched by Mount Sinai investigators.

Regeneron will provide the ETI with access to VelocImmune technology and potential financial support to use the company’s proprietary antibody discovery platform to generate antibodies against targets of interest and explore potential therapeutic applications for human disease.

ETI will undertake preclinical research and Regeneron has an exclusive option to negotiate a license to the antibody for future clinical development and commercialization.

Developed by Regeneron scientists, VelocImmune is a genetic engineering platform that enables the fast and efficient creation of superior fully-human monoclonal antibodies for drug development.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
By Samuel (Tony) Boova, Eda Holl, LaToya Montgomery, Steve Kussick, Nicholas Kigen, Gilbert Olbara, Festus Muigai Njuguna, Terry Vik and Teresa Loile Lotodo
ClinicalTrials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
By Enrique Velazquez-Villarreal
Sponsored

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
By Journal of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account